Bris­tol My­ers is clean­ing up the post-Cel­gene merg­er pipeline, and they’re sweep­ing out an ex­per­i­men­tal check­point in the process

Back dur­ing the lead up to the $74 bil­lion buy­out of Cel­gene, the big biotech’s lead­er­ship did a lit­tle house­clean­ing with a ma­jor pact it had forged with Jounce. Out went the $2.6 bil­lion deal and a col­lab­o­ra­tion on ICOS and PD-1.

Cel­gene, though, al­so added a $530 mil­lion deal — $50 mil­lion up front — to get the world­wide rights to JTX-8064, a drug that tar­gets the LIL­RB2 re­cep­tor on macrophages.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.